{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-056013","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.839742+00:00","generated_at":"2026-06-15T22:50:44.029546+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Liquidia Q1 net loss $11.7M ($0.18/shr); cash $94.4M; YUTREPIA legal appeals advanced","bullets":["Cash $94.4M at March 31, 2023; received $31.8M net from HCRx financing, repaying $22.2M SVB debt.","Revenue $4.5M (up $1.0M YoY) from Promotion Agreement; cost of revenue $0.7M.","R&D $5.3M (+12% YoY); G&A $7.8M (-38% YoY on lower legal fees).","Oral arguments presented May 3 to Federal Circuit in Hatch-Waxman appeal; PTAB appeal also underway.","HCRx revenue interest financing provides up to $100M; $32.5M funded to date with tiered royalty 0.36%-10%."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-056013","json":"https://secwatch.observer/filing/0001104659-23-056013.json","markdown":"https://secwatch.observer/filing/0001104659-23-056013.md","text":"https://secwatch.observer/filing/0001104659-23-056013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923056013/0001104659-23-056013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923056013/tm2314672d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:50:44.029546+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"01e2475beb055995c91c7c1654e8b5600f6050f1","claim":"Liquidia Corp reported Q1 2023 results: revenue $4.5 million, net income -$11.7 million, EPS -$0.18.","evidence_excerpt":"Revenue was $4.5 million for the three months ended March 31, 2023, compared to $3.5 million for the three months ended March 31, 2022. Revenue related primarily to the Promotion Agreement. The increase of $1.0 million was primarily due to increased quantities and favorable gross-to-net rebate adjustments. Cost of revenue was $0.7 million for both the three months ended March 31, 2023 and 2022. Cost of revenue related to the Promotion Agreement as noted above. Research and development expenses were $5.3 million for the three months ended March 31, 2023, compared with $4.7 million for the three months ended March 31, 2022. The increase of $0.6 million or 12% was primarily due to a $0.5 million increase in consulting and personnel expenses in preparation for the potential commercialization of YUTREPIA. General and administrative expenses were $7.8 million for the three months ended March 31, 2023, compared with $12.5 million for the three months ended March 31, 2022. The decrease of $4.7","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923056013/0001104659-23-056013-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q1 2023"},{"label":"Revenue","value":"$4.5 million"},{"label":"Net income","value":"-$11.7 million"},{"label":"EPS","value":"-$0.18"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}